TRX518 + cyclophosphamide

**TRX518 + cyclophosphamide** is an investigational combination therapy for cancer that consists of TRX518, a humanized monoclonal antibody targeting glucocorticoid-induced TNFR family-related gene (GITR), and cyclophosphamide, an alkylating chemotherapeutic and immunosuppressive agent. TRX518 acts as a GITR agonist, designed to activate T effector cells, diminish regulatory T cell (Treg) suppression, and enhance anti-tumor immune responses, while cyclophosphamide modulates the immune environment and damages tumor DNA via alkylation. This combination aims to improve effectiveness against solid tumors by pairing immune-activating and immunosuppressive properties[4][7][8][10].\nTRX518 is developed by Leap Therapeutics and is undergoing clinical trials in combination with cyclophosphamide (and often with avelumab or other agents) for advanced solid tumors[4][10].